Collegium Pharmaceutical Inc (COLL)

Pretax margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	98,568	128,009	141,212	129,912	75,733	21,232	-6,119	-30,562	-28,847	-59,932	-52,327	-34,690	-3,374	42,764	45,293	42,606	27,582	18,119	444	-12,572
Revenue (ttm)	US$ in thousands	631,449	599,245	576,653	566,923	566,767	546,642	536,946	524,949	463,933	361,675	313,505	272,898	276,868	325,777	326,110	321,226	310,016	307,948	301,714	298,696
Pretax margin		15.61%	21.36%	24.49%	22.92%	13.36%	3.88%	-1.14%	-5.82%	-6.22%	-16.57%	-16.69%	-12.71%	-1.22%	13.13%	13.89%	13.26%	8.90%	5.88%	0.15%	-4.21%

December 31, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $98,568K ÷ $631,449K
= 15.61%

The pretax margin of Collegium Pharmaceutical Inc has shown fluctuations over the reported periods from March 31, 2020, to December 31, 2024. The pretax margin started at a negative value of -4.21% in March 2020, indicating that the company was experiencing losses before tax. Over the subsequent quarters, the pretax margin improved slightly, reaching 0.15% by June 2020.

Throughout the rest of 2020 and into 2021, there was a significant positive trend in the pretax margin, with consistent growth reported each quarter. The margin reached a peak of 24.49% by June 30, 2024, reflecting strong profitability before tax.

However, in the following quarters from September 2024 to December 2024, there was a slight decline in the pretax margin, but it remained at a healthy level above 15%.

The overall trend in the pretax margin of Collegium Pharmaceutical Inc shows periods of both growth and decline, with the company experiencing profitability challenges in some quarters but generally maintaining a positive pretax margin over the reported period.